Abbott Laboratories (ABT) Change in Receivables (2009 - 2026)

Abbott Laboratories' Change in Receivables history runs 18 years deep, the most recent figure standing at $42.0 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 83.97% year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at $432.0 million (down 46.13% YoY), while the FY2025 annual figure was $652.0 million, down 5.64% from the prior year.
• Change in Receivables came in at $42.0 million for Q1 2026 at Abbott Laboratories, up from -$222.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $751.0 million in Q1 2022 to a low of -$530.0 million in Q3 2022.
• A 5-year average of $106.4 million and a median of $158.0 million in 2024 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 637.14% in 2022 and fell as far as 280.42% in 2022.
• Abbott Laboratories' Change in Receivables stood at -$341.0 million in 2022, then jumped by 80.06% to -$68.0 million in 2023, then soared by 332.35% to $158.0 million in 2024, then plunged by 240.51% to -$222.0 million in 2025, then surged by 118.92% to $42.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $42.0 million, -$222.0 million, and $202.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison